Aug. 19 at 2:26 PM
$VXRT
Todd Lopeman’s appointment is notable because his background closely matches what Vaxart may need next. Before joining Vaxart, Lopeman spent more than a decade at Dynavax, ultimately serving as SVP of Technical Operations, overseeing vaccine manufacturing, process development, engineering, validation and CMC activities. That experience could be especially relevant now that Dynavax is owned by Sanofi and Sanofi has potential responsibility for further COVID-19 development under the agreement.
One interpretation is that Vaxart is strengthening manufacturing and CMC readiness ahead of a possible technology transfer to Sanofi. Lopeman’s familiarity with Dynavax’s technical organization could reduce execution risk if that occurs. But his experience also fits broader VAAST platform needs across norovirus and influenza. The hire doesn’t prove Sanofi intends to proceed, but the timing and unusually relevant background make it a potentially meaningful signal.
